Claire Baker, MD
Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1124057559
Payments from drug & device makers
Across 1,482 payments — averaging $363.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$394K
- Sanofi US Services Inc.$60K
- Medtronic$38K
- AbbVie$19K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- AstraZeneca$8K
- plus $6K from 43 others
Across 3 payments — averaging $309.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$927
What the payments were for
- Speaking & faculty fees$1252%
- Food & beverage$5,50298%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$538,493 in reported general payments places this provider in the 90th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 342 | $422,847 |
| TrulicityDulaglutide | 308 | $364,969 |
| JardianceEmpagliflozin | 305 | $305,419 |
| MounjaroTirzepatide | 180 | $201,531 |
| Tresiba Flextouch U-100Insulin Degludec | 235 | $164,423 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 86 | $125,393 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $111,756 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 159 | $80,842 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $79,168 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 108 | $77,694 |
| Tresiba Flextouch U-200Insulin Degludec | 67 | $74,228 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 106 | $52,928 |
| JanuviaSitagliptin Phosphate | 60 | $52,528 |
| Novolog FlexpenInsulin Aspart | 194 | $44,552 |
| Humalog Kwikpen U-100Insulin Lispro | 177 | $39,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $503 | $595,184633 claims |
| Novo NordiskOzempic, Novolog, Fiasp | $467 | $461,051453 claims |
| Boehringer IngelheimJardiance, Tradjenta | $44 | $322,668330 claims |
| AbbVieSynthroid, Armour Thyroid | $18,627 | $27,540340 claims |
| AstraZenecaFarxiga | $7,737 | $20,21621 claims |
| Antares Pharma, Inc.Xyosted | $285 | $7,28512 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $5,974805 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Omaha
- Cyrus DesouzaOmaha$3.6M
- Vijay ShivaswamyOmaha$1.3M
- Robert AndersonOmaha$736K
- Sarah KonigsbergOmaha$251K
- Andjela DrincicOmaha$192K
- Marium IlahiOmaha$170K
- Robert ReckerOmaha$115K
- Timothy WahlOmaha$41K
- Marc RendellOmaha$25K
- Anery PatelOmaha$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.